Havana - The restrictions of the U.S. economic, commercial and financial blockade against Cuba affect Cuban foreign trade and hinder the development of the foreign investment.

According to the report carried out from April 2015 to April 2016, the losses due to the blockade in this period amounted to $4.10 billion USD, a much higher figure compared to the previous period.

Health and biotechnology are the sectors most affected by this economic and commercial siege.

American citizens and sometimes citizens from other countries were denied access to more than 200 quality medical programs offered by the Caribbean nation, at a loss of over $31 million USD during the period.

The sale of the Cuban drug Heberprot-P (which aids feet care for those with diabetics) to only 5% of the American population would earn the Cuban biotechnology industry around $122 million USD annually.

Other drugs such as Melagenina Plus, Coriodermina and Piloactive Lotion -to treat vitiligo, psoriasis and alopecia, respectively - would benefit much of the U.S. population and generate big profits for Cuba in turn.

Another Cuban biotechnology industry drug is Vidatox 30CH, a treatment for patients with cancer, which Americans are banned from purchasing. The export of this medicine to the United States would generate an income of about $900 million USD.

The lifting of the 50-year blockade would mutually benefit both countries.